{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:58:23Z","timestamp":1772009903751,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2167\/1"],"award-info":[{"award-number":["EXC2167\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01637-2","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:30:05Z","timestamp":1769171405000},"page":"1367-1383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Risankizumab\u2019s Long-Term Effects in Psoriasis Using Optical Coherence Tomography"],"prefix":"10.1007","volume":"16","author":[{"given":"Henner","family":"Zirpel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh","family":"Ha-Wissel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hobelsberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Pommerien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Beissert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Gaffal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenia","family":"Neumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"19","key":"1637_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"key":"1637_CR2","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1637_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamadermatol.2015.6262","volume":"152","author":"AS Lonnberg","year":"2016","unstructured":"Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Association of psoriasis with the risk for type\u00a02 diabetes mellitus and obesity. JAMA Dermatol. 2016;152(7):761\u20137.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1637_CR4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.15840","volume":"48","author":"F Yamazaki","year":"2021","unstructured":"Yamazaki F. Psoriasis: comorbidities. J Dermatol. 2021;48(6):732\u201340.","journal-title":"J Dermatol"},{"issue":"2","key":"1637_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","volume":"9","author":"J de Korte","year":"2004","unstructured":"de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140\u20137.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1637_CR6","doi-asserted-by":"publisher","first-page":"715839","DOI":"10.3389\/fimmu.2021.715839","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Yang Z, Tang K, Sun Q, Jin H. Stigmatization in patients with psoriasis: a mini review. Front Immunol. 2021;12:715839.","journal-title":"Front Immunol"},{"issue":"4","key":"1637_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1637_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","volume":"90","author":"R Heidenreich","year":"2009","unstructured":"Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90(3):232\u201348.","journal-title":"Int J Exp Pathol"},{"key":"1637_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010059","author":"Y Chen","year":"2023","unstructured":"Chen Y, Tai Z, Zhu C, Yu Q, Zhu Q, Chen Z. Vascular endothelial growth factor\u00a0A VEGFA inhibition: an effective treatment strategy for psoriasis. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms25010059.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1637_CR10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jid.2024.02.013","volume":"144","author":"Q Li","year":"2024","unstructured":"Li Q, Pang B, Dang E, Wang G. Endothelial dysfunction in psoriasis: an integrative review. J Invest Dermatol. 2024;144(9):1935\u201342.","journal-title":"J Invest Dermatol"},{"key":"1637_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3410\/B2-40","volume":"2","author":"P Di Meglio","year":"2010","unstructured":"Di Meglio P, Nestle FO. The role of IL23 in the immunopathogenesis of psoriasis. F1000 Biol Rep. 2010;2:40.","journal-title":"F1000 Biol Rep"},{"issue":"9","key":"1637_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1637_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"1","key":"1637_CR14","doi-asserted-by":"publisher","first-page":"17675","DOI":"10.1038\/s41598-019-53240-z","volume":"9","author":"AK Kannan","year":"2019","unstructured":"Kannan AK, Su Z, Gauvin DM, et al. IL-23 induces regulatory T\u00a0cell plasticity with implications for inflammatory skin diseases. Sci Rep. 2019;9(1):17675.","journal-title":"Sci Rep"},{"issue":"77","key":"1637_CR15","doi-asserted-by":"publisher","first-page":"eabq3254","DOI":"10.1126\/sciimmunol.abq3254","volume":"7","author":"SK Whitley","year":"2022","unstructured":"Whitley SK, Li M, Kashem SW, et al. Local IL-23 is required for proliferation and retention of skin-resident memory T(H)17 cells. Sci Immunol. 2022;7(77):eabq3254.","journal-title":"Sci Immunol"},{"issue":"4","key":"1637_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7(4):778\u201391.","journal-title":"MAbs"},{"issue":"10198","key":"1637_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"8","key":"1637_CR18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.17109","volume":"35","author":"D Thaci","year":"2021","unstructured":"Thaci D, Soliman AM, Eyerich K, et al. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naive patients with moderate to severe plaque psoriasis: a phase\u00a03 clinical trial. J Eur Acad Dermatol Venereol. 2021;35(8):1686\u201391.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1637_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1637_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.abd.2024.08.002","volume":"100","author":"TF Cestari","year":"2024","unstructured":"Cestari TF, Souza CDS, Azulay-Abulafia L, et al. Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase\u00a03 study with an open-label extension period in Brazil. An Bras Dermatol. 2024;100(2):260\u201371.","journal-title":"An Bras Dermatol"},{"issue":"12","key":"1637_CR21","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jdv.16521","volume":"34","author":"B Strober","year":"2020","unstructured":"Strober B, Menter A, Leonardi C, et al. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase\u00a0III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020;34(12):2830\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1637_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s13555-021-00679-6","volume":"12","author":"JJ Crowley","year":"2022","unstructured":"Crowley JJ, Langley RG, Gordon KB, et al. Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: subgroup analysis from the IMMerge study. Dermatol Ther (Heidelb). 2022;12(2):561\u201375.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1637_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase\u00a02\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"issue":"6","key":"1637_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase\u00a03 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358.","journal-title":"JAMA Dermatol"},{"issue":"10148","key":"1637_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase\u00a03 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"5","key":"1637_CR26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jdv.19748","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Bachelez H, Crowley J, et al. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256\u00a0weeks (LIMMitless trial). J Eur Acad Dermatol Venereol. 2024;38(5):864\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1637_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00964-6","author":"KA Papp","year":"2025","unstructured":"Papp KA, Lebwohl MG, Puig L, et al. Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless phase\u00a03, open-label extension trial results. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00964-6.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1637_CR28","doi-asserted-by":"publisher","first-page":"17331","DOI":"10.1038\/s41598-023-44478-9","volume":"13","author":"CI Moon","year":"2023","unstructured":"Moon CI, Lee J, Baek YS, Lee O. Psoriasis severity classification based on adaptive multi-scale features for multi-severity disease. Sci Rep. 2023;13(1):17331.","journal-title":"Sci Rep"},{"issue":"5","key":"1637_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.17219\/acem\/69804","volume":"26","author":"A Bozek","year":"2017","unstructured":"Bozek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851\u20136.","journal-title":"Adv Clin Exp Med"},{"issue":"5035","key":"1637_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1126\/science.1957169","volume":"254","author":"D Huang","year":"1991","unstructured":"Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254(5035):1178\u201381.","journal-title":"Science"},{"issue":"Suppl 2","key":"1637_CR31","doi-asserted-by":"publisher","first-page":"ii40","DOI":"10.1136\/bjophthalmol-2013-304299","volume":"98","author":"CA Medina","year":"2014","unstructured":"Medina CA, Plesec T, Singh AD. Optical coherence tomography imaging of ocular and periocular tumours. Br J Ophthalmol. 2014;98(Suppl 2):ii40\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1637_CR32","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1524-4725.2009.01164.x","volume":"35","author":"M Mogensen","year":"2009","unstructured":"Mogensen M, Joergensen TM, Nurnberg BM, et al. Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. Dermatol Surg. 2009;35(6):965\u201372.","journal-title":"Dermatol Surg"},{"issue":"1","key":"1637_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pdpdt.2013.11.003","volume":"11","author":"L Themstrup","year":"2014","unstructured":"Themstrup L, Banzhaf CA, Mogensen M, Jemec GB. Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions. Photodiagnosis Photodyn Ther. 2014;11(1):7\u201312.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"2","key":"1637_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/eye.2017.181","volume":"32","author":"ACS Tan","year":"2018","unstructured":"Tan ACS, Tan GS, Denniston AK, et al. An overview of the clinical applications of optical coherence tomography angiography. Eye Lond. 2018;32(2):262\u201386.","journal-title":"Eye Lond"},{"issue":"4","key":"1637_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.det.2017.06.008","volume":"35","author":"A Levine","year":"2017","unstructured":"Levine A, Wang K, Markowitz O. Optical coherence tomography in the diagnosis of skin cancer. Dermatol Clin. 2017;35(4):465\u201388.","journal-title":"Dermatol Clin"},{"issue":"2","key":"1637_CR36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-017-0175-4","volume":"7","author":"S Schuh","year":"2017","unstructured":"Schuh S, Holmes J, Ulrich M, et al. Imaging blood vessel morphology in skin: dynamic optical coherence tomography as a novel potential diagnostic tool in dermatology. Dermatol Ther (Heidelb). 2017;7(2):187\u2013202.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1637_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/lsm.22788","volume":"50","author":"AJ Deegan","year":"2018","unstructured":"Deegan AJ, Talebi-Liasi F, Song S, et al. Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med. 2018;50(3):183\u201393.","journal-title":"Lasers Surg Med"},{"issue":"2","key":"1637_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00403-009-1000-4","volume":"302","author":"H Morsy","year":"2010","unstructured":"Morsy H, Kamp S, Thrane L, et al. Optical coherence tomography imaging of psoriasis vulgaris: correlation with histology and disease severity. Arch Dermatol Res. 2010;302(2):105\u201311.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1637_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/srt.12096","volume":"20","author":"H Zafar","year":"2014","unstructured":"Zafar H, Enfield J, O\u2019Connell ML, Ramsay B, Lynch M, Leahy MJ. Assessment of psoriatic plaque in vivo with correlation mapping optical coherence tomography. Skin Res Technol. 2014;20(2):141\u20136.","journal-title":"Skin Res Technol"},{"key":"1637_CR40","doi-asserted-by":"publisher","first-page":"995883","DOI":"10.3389\/fmed.2022.995883","volume":"9","author":"L Ha-Wissel","year":"2022","unstructured":"Ha-Wissel L, Yasak H, Huber R, et al. Case report: optical coherence tomography for monitoring biologic therapy in psoriasis and atopic dermatitis. Front Med. 2022;9:995883.","journal-title":"Front Med"},{"issue":"1","key":"1637_CR41","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1111\/jdv.20097","volume":"39","author":"L Ha-Wissel","year":"2025","unstructured":"Ha-Wissel L, Grasshoff H, Gob M, et al. Optical coherence tomography-based imaging biomarkers for disease activity monitoring in plaque psoriasis. J Eur Acad Dermatol Venereol. 2025;39(1):e78\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1637_CR42","unstructured":"Validity of Outcome Measures, in: Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the Treatment of Adult Patients with Moderate-to-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy. Canadian Agency for Drugs and Technologies in Health. 2018; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534046\/. Accessed Nov 2025."},{"issue":"6","key":"1637_CR43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.clindermatol.2007.08.005","volume":"25","author":"M Murphy","year":"2007","unstructured":"Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524\u20138.","journal-title":"Clin Dermatol"},{"issue":"9","key":"1637_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/DSS.0000000000000457","volume":"41","author":"A Mamalis","year":"2015","unstructured":"Mamalis A, Ho D, Jagdeo J. Optical coherence tomography imaging of normal, chronologically aged, photoaged and photodamaged skin: a systematic review. Dermatol Surg. 2015;41(9):993\u20131005.","journal-title":"Dermatol Surg"},{"key":"1637_CR45","doi-asserted-by":"publisher","first-page":"100611","DOI":"10.1016\/j.pacs.2024.100611","volume":"38","author":"X Li","year":"2024","unstructured":"Li X, Yew YW, Vinod Ram K, et al. Structural and functional imaging of psoriasis for severity assessment and quantitative monitoring of treatment response using high-resolution optoacoustic imaging. Photoacoustics. 2024;38:100611.","journal-title":"Photoacoustics"},{"issue":"1","key":"1637_CR46","doi-asserted-by":"publisher","first-page":"15121","DOI":"10.1038\/s41598-024-65902-8","volume":"14","author":"Q Jiang","year":"2024","unstructured":"Jiang Q, Qu Z, Wang B, et al. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-interleukin-17A monoclonal antibody: an observational study. Sci Rep. 2024;14(1):15121.","journal-title":"Sci Rep"},{"issue":"6","key":"1637_CR47","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/lsm.23551","volume":"54","author":"S Felice","year":"2022","unstructured":"Felice S, Bressler MY, Karim R, Markowitz O. Transforming the treatment of psoriasis to the 21st century: detecting subclinical therapeutic response to secukinumab using optical coherence tomography as a prognostic indicator. Lasers Surg Med. 2022;54(6):825\u201334.","journal-title":"Lasers Surg Med"},{"issue":"2","key":"1637_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/app15020535","volume":"15","author":"HB Wirsching","year":"2025","unstructured":"Wirsching HB, Mayer OJ, Schlingmann S, et al. Line-field confocal optical coherence tomography of plaque psoriasis under IL-17 inhibitor therapy: artificial intelligence-supported analysis. Appl Sci. 2025;15(2):535.","journal-title":"Appl Sci"},{"issue":"1","key":"1637_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2019.06.002","volume":"95","author":"K Kurihara","year":"2019","unstructured":"Kurihara K, Fujiyama T, Phadungsaksawasdi P, Ito T, Tokura Y. Significance of IL-17A-producing CD8(+)CD103(+) skin resident memory T\u00a0cells in psoriasis lesion and their possible relationship to clinical course. J Dermatol Sci. 2019;95(1):21\u20137.","journal-title":"J Dermatol Sci"},{"issue":"21","key":"1637_CR50","doi-asserted-by":"publisher","first-page":"11251","DOI":"10.3390\/ijerph182111251","volume":"18","author":"M Kasprowicz-Furmanczyk","year":"2021","unstructured":"Kasprowicz-Furmanczyk M, Czerwinska J, Placek W, Owczarczyk-Saczonek A. Assessment of the tissue resident memory cells in lesional skin of patients with psoriasis and in healthy skin of healthy volunteers. Int J Environ Res Public Health. 2021;18(21):11251.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"1637_CR51","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bjd.20963","volume":"186","author":"L Puig","year":"2022","unstructured":"Puig L, Costanzo A, Munoz-Elias EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022;186(5):773\u201381.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1637_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/1523-1747.ep12497850","volume":"78","author":"IM Braverman","year":"1982","unstructured":"Braverman IM, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol. 1982;78(1):12\u20137.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1637_CR53","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4103\/0019-5154.91820","volume":"56","author":"S Gupta","year":"2011","unstructured":"Gupta S, Kaur M, Gupta R, Singh S, Pant L, Singh PP. Dermal vasculature in psoriasis and psoriasiform dermatitis: a morphometric study. Indian J Dermatol. 2011;56(6):647\u20139.","journal-title":"Indian J Dermatol"},{"issue":"1","key":"1637_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1087-0024.2000.00010.x","volume":"5","author":"IM Braverman","year":"2000","unstructured":"Braverman IM. The cutaneous microcirculation. J Invest Dermatol Symp Proc. 2000;5(1):3\u20139.","journal-title":"J Invest Dermatol Symp Proc"},{"key":"1637_CR55","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/j.1749-6632.1964.tb52565.x","volume":"116","author":"JP Kulka","year":"1964","unstructured":"Kulka JP. Microcirculatory impairment as a factor in inflammatory tissue damage. Ann N Y Acad Sci. 1964;116:1018\u201344.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"1637_CR56","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.1994.tb08582.x","volume":"131","author":"M Goodfield","year":"1994","unstructured":"Goodfield M, Hull SM, Holland D, et al. Investigations of the \u2018active\u2019 edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin. Br J Dermatol. 1994;131(6):808\u201313.","journal-title":"Br J Dermatol"},{"key":"1637_CR57","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015354","author":"P Di Meglio","year":"2014","unstructured":"Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014. https:\/\/doi.org\/10.1101\/cshperspect.a015354.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"1637_CR58","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","volume":"384","author":"A Waxman","year":"2021","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325\u201334.","journal-title":"N Engl J Med"},{"key":"1637_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172058","author":"J May","year":"2023","unstructured":"May J, Mitchell JA, Jenkins RG. Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI172058.","journal-title":"J Clin Invest"},{"issue":"12","key":"1637_CR60","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41574-023-00893-6","volume":"19","author":"I AlZaim","year":"2023","unstructured":"AlZaim I, de Rooij L, Sheikh BN, Borgeson E, Kalucka J. The evolving functions of the vasculature in regulating adipose tissue biology in health and obesity. Nat Rev Endocrinol. 2023;19(12):691\u2013707.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1637_CR61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000210760","volume":"1","author":"RC Hermann","year":"1988","unstructured":"Hermann RC, Ellis CN, Fitting DW, Ho VC, Voorhees JJ. Measurement of epidermal thickness in normal skin and psoriasis with high-frequency ultrasound. Skin Pharmacol. 1988;1(2):128\u201336.","journal-title":"Skin Pharmacol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01637-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01637-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:02:33Z","timestamp":1772006553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01637-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01637-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Henner Zirpel is a salaried employee of Almirall Hermal GmbH, Reinbeck, Germany, and has received support for meeting attendance and\/or travel from Pfizer, UCB Pharma, Almirall, Janssen, and TriNetX. Linh Ha-Wissel has received support for meeting attendance and travel from AbbVie. Sarah Hobelsberger reported clinical trial support from Almirall and Pierre Fabre, advisor\u2019s honoraria from Almirall, AbbVie, and Bristol Myers Squibb, speaker\u2019s honoraria from Almirall, UCB, Bristol Myers Squibb, and AbbVie, and travel support from UCB, Janssen Cilag, Almirall, Novartis, Lilly, LEO Pharma, and AbbVie. Stefan Beissert has served as consultant\/advisor for AbbVie Deutschland GmbH & Co, Actelion Pharmaceuticals GmbH, Almirall-Hermal GmbH, Amgen GmbH, Celgene GmbH, Galderma Laboratorium GmbH, Janssen Cilag GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, Menlo Therapeutics, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Sanofi-Aventis Deutschland GmbH, UCB Pharma GmbH. He has received speaker\u2019s honoraria from Novartis Pharma GmbH, AbbVie Deutschland GmbH & Co, MSD, Pfizer, Janssen-Cilag, Roche-Posay, Actelion, GSK, Bristol Myers Squibb, Celgene GmbH, Almirall-Hermal GmbH, Hexal-Sandoz, Sanofi-Aventis Deutschland GmbH. Evelyn Gaffal has served as an investigator and\/or consultant\/advisor for AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen Cilag, LEO Pharma, Novartis, Sanofi, and UCB. She has received grants from Almirall and Sanofi. Ruth Bauer, Jenia Neumeister, and Kristina Lohmann are salaried employees of AbbVie Deutschland GmbH & Co. KG and may own stock\/options. Diamant Tha\u00e7i has served as an investigator and\/or consultant\/advisor for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galderma, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, La Roche Possay, New Bridge, Novartis, Regeneron, Sandoz, Sanofi, Samsung, Pfizer, Target-RWE Solution, UCB, and Vichy. He has received grants from AbbVie, LEO Pharma, and Novartis. Lena Pommerien has nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval for the study was granted through the local ethics committee of the University of L\u00fcbeck for prospective inclusion of the patients (old ethics file number #20-170A, new file number #2023-800) and for the subsequent analysis (#22-133). All individuals provided written informed consent upfront for inclusion in the study. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}